GENSIght BUY | TP EUR14 Initiation of coverage
GenSight shares have recently been depressed in spite of re-affirming newsflow. In today’s market of elevated early stage valuations, we like the contrarian appeal GenSight offers investors, with a large array of data establishing efficacy and safety – we believe its time investors revisit why LUMEVOQ could receive approval in LHON in the next 18 months.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.